Thermalin Diabetes LLC
Three takes on next-generation insulin analogs
This article was originally published in Start Up
Thermalin Diabetes LLC is developing candidates aimed at three separate segments of the insulin analog market, the first, a rapid-acting, ultra-concentrated insulin will complete preclinical proof-of-concept studies this spring. A second, ultra-rapid-acting insulin analog is designed to make mealtime dosing more effective. Finally, Thermalin has figured out a way to make both basal and rapid-acting insulins that are stable in the heat, potentially enabling important new ways to get insulin to patients.
You may also be interested in...
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.
Fueled by a series of strategic acquisitions, Patheon hopes to become the biopharma industry’s first single-source, end-to-end manufacturing service provider.
The demands of building new biotechs can take their toll, yet Alan Crane wears his 52 years and over two decades of high-risk biotech start-up investing lightly. He's built an exceptional number of companies during his tenure at Polaris, many of which have proved to be among the industry’s more successful emerging ventures.